Reply to correspondence from Inzelberg et al.—“onset age of Parkinson disease”

Zareparsi, Sepideh; Payami, Haydeh

doi:10.1002/ajmg.10581

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these symptoms are the most characteristic, other non-motor features also appear in PD: autonomic dysfunction, mood disorders, sleep disorders, cognitive impairment, gastrointestinal symptoms, and pain [ 16 , 17 ]. The mean age of the onset of symptoms of PD was estimated to be in the late fifties; however, with the increase in the average age, the mean age of symptom onset has risen to the sixties [ 18 , 19 , 20 ]. All existing treatments are aimed at alleviating symptoms and there is currently no therapeutic treatment to cure PD.…”

Section: Introductionmentioning

confidence: 99%

Current Treatments and New, Tentative Therapies for Parkinson’s Disease

Pardo-Moreno¹,

García‐Morales

Suleiman‐Martos

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative pathology, the origin of which is associated with the death of neuronal cells involved in the production of dopamine. The prevalence of PD has increased exponentially. The aim of this review was to describe the novel treatments for PD that are currently under investigation and study and the possible therapeutic targets. The pathophysiology of this disease is based on the formation of alpha-synuclein folds that generate Lewy bodies, which are cytotoxic and reduce dopamine levels. Most pharmacological treatments for PD target alpha-synuclein to reduce the symptoms. These include treatments aimed at reducing the accumulation of alpha-synuclein (epigallocatechin), reducing its clearance via immunotherapy, inhibiting LRRK2, and upregulating cerebrosidase (ambroxol). Parkinson’s disease continues to be a pathology of unknown origin that generates a significant social cost for the patients who suffer from it. Although there is still no definitive cure for this disease at present, there are numerous treatments available aimed at reducing the symptomatology of PD in addition to other therapeutic alternatives that are still under investigation. However, the therapeutic approach to this pathology should include a combination of pharmacological and non-pharmacological strategies to maximise outcomes and improve symptomatological control in these patients. It is therefore necessary to delve deeper into the pathophysiology of the disease in order to improve these treatments and therefore the quality of life of the patients.

show abstract